ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts ...

TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.

"ICON Public Limited Company (NASDAQ:ICLR): The stock pulled back on news that biotechnology funding has dropped, albeit from very strong growth levels. We continue to believe the company is a ...

Shares tumbled over 10%, leading a chip sell-off as China's new AI model prompted fresh questions on Big Tech's investments.

B, consensus $8.5B. CEO Steve Cutler commented, “ICON (ICLR) continues to navigate dynamic clinical development ...

Michael Ryskin, an analyst from Bank of America Securities, maintained the Buy rating on Icon (ICLR – Research Report). The associated price ...